**HMG-CoA reductase inhibitors: an updated review of biosynthesis and patent prospecting**

**Inhibidores da HMG-CoA redutase: uma revisão atualizada da prospecção de biossíntese e patentes**

Received: 10/06/2022 | Revised: 10/26/2022 | Accepted: 10/30/2022 | Published: 11/04/2022

**Uiara Maria de Barros Lira Lins**
ORCID: https://orcid.org/0000-0002-6007-9932
Universidade Federal Rural de Pernambuco, Brasil
E-mail: uiaramaril@gmail.com

**Valberto Barbosa de Oliveira**
ORCID: https://orcid.org/0000-0002-4616-6917
Universidade Católica de Pernambuco, Brasil
E-mail: valberto.oliveira88@gmail.com

**Adriana Ferreira de Souza**
ORCID: https://orcid.org/0000-0002-9527-2206
Universidade Católica de Pernambuco, Brasil
E-mail: adriana.souza@unicap.br

**Dayana Montero Rodríguez**
ORCID: https://orcid.org/0000-0001-8954-7309
Universidade Federal de Pernambuco, Brasil
E-mail: dayanamontero87@gmail.com

**Sérgio Selisman Silva Dantas**
ORCID: https://orcid.org/0000-0002-6431-0265
Universidade Católica de Pernambuco, Brasil
E-mail: sergiosexualisman808@gmail.com

**Marcos Antônio Barbosa de Lima**
ORCID: https://orcid.org/0000-0001-5987-224X
Universidade Federal Rural de Pernambuco, Brasil
E-mail: marcos.barbosalima@ufprp.br

**Rosileide Fontenele da Silva Andrade**
ORCID: https://orcid.org/0000-0001-8526-554X
Universidade Católica de Pernambuco, Brasil
E-mail: rosileide.andrade@unicap.br

**Galba Maria de Campos-Takaki**
ORCID: https://orcid.org/0000-0002-0519-0849
Universidade Católica de Pernambuco, Brasil
E-mail: galba.takaki@unicap.br

**Abstract**

HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is the enzyme that plays a limiting role in cholesterol biosynthesis. Among the HMG-CoA reductase inhibitor molecules, statins stand out, a class of drug used in the treatment of atherosclerosis and in the reduction of high cholesterol levels, therefore they are biomolecules of medical and pharmaceutical importance. In this context, this work aimed to carry out a systematic mapping of patents and scientific articles related to the biosynthesis of HMG-CoA reductase inhibitors. The search was carried out in the databases of the National Institute of Intellectual Property (INPI), the European Patent Office (Espacenet), the Derwent Innovations Index, the World Intellectual Property Organization (WIPO) and also articles indexed in Scielo and Pubmed using as descriptors “statins”; “production and statins and fungi”; “statins and fungus”. Of the 2561 cataloged patents, 09 were included because they met the inclusion criteria. The number of scientific articles found in the databases was higher (2820) when compared to the number of patents. As a country, China represents the largest holder on the subject, corresponding to 88.9% of patented products. Based on the mapping, advances in the search for strategies for the biotechnological production of statins can be highlighted. Some of the inventions used microorganisms such as filamentous fungi associated with agro-industrial substrates as an alternative and low-cost source for the production of statins to replace synthetic sources. However, future studies can be carried out using new fungi and new renewable substrates, considering the existing biodiversity worldwide.

**Keywords:** Statins; Fungi; Renewable substrates; Biopharmaceutical.
Resumen

La HMG-CoA reductasa (3-hidroxi-3-metilglutaril-coenzima A reductasa) es la enzima que juega un papel limitante en la biosíntesis del colesterol. Entre las moléculas inhibidoras de la HMG-CoA reductasa destacan las estatinas, una clase de fármaco utilizada en el tratamiento de la aterosclerosis y en la reducción de los niveles elevados de colesterol, por lo que son biomoléculas de importancia médica y farmacéutica. En este contexto, este trabajo tuvo como objetivo realizar un mapeo sistemático de patentes y artículos científicos relacionados con la biosíntesis de inhibidores de la HMG-CoA reductasa. La búsqueda se realizó en las bases de datos del Instituto Nacional de Propiedad Intelectual (INPI), la Oficina Europea de Patentes (Espacenet), el Derwent Innovations Index, la Organización Mundial de la Propiedad Intelectual (WIPO) y también artículos indexados en Scielo y Pubmed utilizando como descriptores “estatinas”, “producción y estatinas e hongos”, “estatinas e fungos”. De las 2561 patentes catalogadas, se incluyeron 09 porque cumplían con los criterios de inclusión. El número de artículos científicos encontrados en las bases de datos fue superior (2820) cuando comparado al número de patentes. Como país, China representa el mayor detentor sobre la temática, correspondiendo a 88,9% de los productos patentados. A partir de este mapeo, se pueden destacar avances en la búsqueda por estrategias para producción biotecnológica de estatinas. Algunas de las invenciones utilizaron microorganismos como hongos filamentosos asociados a substratos agroindustriales como fonte alternativa y de bajo costo para producción de estatinas en substitución a fuentes sintéticas. En el contexto, existe una lacuna que puede ser preenchida pela atividade de novos fungos e de novos substratos renováveis, que ainda não foram pesquisados, considerando a biodiversidade existente mundialmente.

Palabras clave: Estatinas; Fungos; Substratos renováveis; Biofármaco.

1. Introduction

HMG-CoA reductase (3-hidroxy-3-metilglutaril-coenzyyme A reductase or HMGR) is an enzyme of the mevalonate pathway responsible for the synthesis of cholesterol. It is an enzyme that is a target for numerous drugs, as it participates in the rate-limiting step of endogenous production of cholesterol (Cedraz; Lavorato, 2020; Ram et al, 2021). Among the drugs most used in the treatment of dyslipidemia are statins, which because they have structural similarity to the substrate 3-hydroxy-3 methylglutaryl CoA (HMG-CoA), inhibit the enzyme HMG-CoA reductase (EC. 1.1.1.34), essential for the cholesterol biosynthesis (Morofuji et al., 2022; Mouafi; Ibrahim; Elsoud, 2016).

The world market for HMG-CoA reductase inhibitors (statins) is estimated at 39.8 billion by 2025 according to iHealthcareAnalyst. The role of this clastherapy in the reduction of lipids in the blood is already evidenced, however, studies clinical evidence evidence other beneficial effects of statins exhibiting action anti-inflammatory, antioxidant and immunomodulatory, providing them with an therapeutic in the treatment of various diseases (Kashour et al., 2021; Mihos; Pineda; Santa, 2014).

Biotechnological production is preferred for industrial production ofHMG-CoA reductase inhibitors that can be produced as metabolites secondary to several microorganisms, such as Penicillium sp., Monascus ruber and Aspergillus terreus (Gholami-Shabani et al., 2022; Moreira et al., 2018).
Filamentous fungi are the main producers of statins considering the presence of an enzyme system analogous to that of humans, Cytochrome P450 (CYP,P450), responsible for drug metabolism. These biomolecules are produced basically biosynthetically by submerged fermentation (Hasan et al., 2022; Huang; Liao; Li, 2018; Mclean et al., 2015).

HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase or HMGR) is an enzyme of the mevalonate pathway responsible for the synthesis of cholesterol. It is enzyme is a target for numerous drugs available on the market to reduce the levels of cholesterol, known as statins that participate in the limiting step of production endogenous cholesterol. The main drugs available on the market are: Simvastatin, Pravastatin, Atorvastatin, Rosuvastatin (Morofuji et al., 2022; Cedraz; Lavorato, 2020; Mouafi; Ibrahim; Elsoud, 2016).

Cardiovascular diseases are the leading cause of death worldwide according to World Health Organization (WHO), representing 32% of total global deaths. In Brazil, more than 39 thousand people died from January to February 5, 2022 due to heart diseases according to the Brazilian Society of Cardiology (SBC). In this in this sense, the public health problem worsens even more, when added to the pandemic caused by the new coronavirus, since patients with infection caused by SARS-CoV-2 poses risks of cardiovascular and thrombotic complications, increasing the number of patients (Yahin; Ylgün, 2022; Kashour et al., 2021; Lima Martínez et al., 2020).

It is also noteworthy that hypercholesterolemia is considered an important factor risk of coronary heart disease in humans. In this sense, several studies epidemiological studies demonstrate a direct relationship between cardiovascular diseases (CVD) and atherosclerosis at high levels of total blood cholesterol (Alizadehsani et al., 2022; Neto et al., 2019; González-Rivas et al., 2018).

In this context, the current world trend is the search for a bioprocess efficient and sustainable for the production of biomolecules with high added value, however, a major challenge is to find microorganisms with high enzymatic potential that allows the production of these biomolecules. The biotechnological production of the HMG-CoA reductase inhibitor gains prominence due to the possibilities of using renewable and low-cost sources for their achievement, contributing to the essential requirements of sustainability (Morofuji et al., 2022; Mahmoud; Abdel_Hadi, 2022; Kashour et al., 2021; Suwannarat et al., 2019; Mouafi; Ibrahim; Elsoud, 2016; Jaivel; Marimuthu, 2010).

The production of new drugs and medicines requires the prospect of information obtained from scientific articles and patents. Therefore, this review aims to objective to carry out a technological prospection and provide an updated overview of the innovations regarding the biotechnological production of HMG-CoA reductase inhibitor through patents deposited in open access banks using fungi as statin producers as well as the methods used to obtain these biomolecules.

2. Methodology

The study in question is a technological prospection, which aims to present and discuss the systematic mapping of scientific development through patents and technological development of the biosynthesis of HMG-CoA reductase inhibitors. The research was carried out from January from 2015 to July 2022. The searches were carried out in the Institute’s database Industrial Property National Institute (INPI) (https://gri.inpi.gov.br/), aiming at the analysis of patents deposited in national territory. In addition, there were also research was carried out in the Derwent Innovations Index – DII (Web of Science/Clarivate Analytics), European Patent Office (Espacenet) (https://worldwide.espacenet.com), being known to have patent applications for approximately 100 countries and World Intellectual Property Organization (WIPO) (https://www.wipo.int), since it has a wider range of patents.

On the other hand, research in scientific articles was carried out on the basis of dados Scielo (Scientific Electronic Library Online), Pubmed (U.S National Library of Medicine National Institutes of Health). Descriptors and natural language
were used in combination with Boolean operators from the terms and their correlates “statins”, “production and statins and fungi”, “statins and fungus”. The criteria for inclusion applied to the results were: (1) the text available in full; (2) articles and patents published between 2015-2022; (3) written in Portuguese, English or Spanish and, finally, (4) be directly related to the object of study here introduced.

The journals resulting from the search were analyzed based on inhibitors of HMG-CoA reductase produced by fungi, and the use of agro-industrial substrates for their production. At the same time, the patents found were distributed in patents containing HMG-CoA reductase inhibitors and redistributed by patents related to the types of HMG-CoA reductase inhibitors and their production biotechnology. Finally, the data obtained were stored and processed in the Microsoft Excel (Microsoft Office®2016) for interpretation and discussion of results.

3. Results and Discussion

3.1 Mapping of Biotechnological Production of HMG-CoA Reductase Inhibitors

According to Tigre and Kupfer (2004), technological monitoring through patents aims at the development scientific and technological linked to the expansion of knowledge that are capable of contribute to decision making and the search for new technologies and innovations.

The results obtained through the content analysis were identified 2561 patents through a search in the databases on the four platforms according to the descriptors conform (Table 1). It can be seen that, according to Table 1, the Derwent Innovations Index base is the one that holds the largest number of patents on the subject, with 1303 patents found, followed by World Intellectual property (WIPO) with 1028 and a European Patent Office (Espacenet) with 228 patents.

<table>
<thead>
<tr>
<th>Table 1 - Number of patents by keywords in title and abstract found in the databases used for research in the period from 2015 to 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Descriptors</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>Statins</td>
</tr>
<tr>
<td>Production and statins e fungi</td>
</tr>
<tr>
<td>Statins and fungi</td>
</tr>
<tr>
<td>Total:</td>
</tr>
</tbody>
</table>

Source: Authors.

At the National Institute of Industrial Property (INPI), 02 patent registration. However, as Brazil is part of the Cooperation Treaty of Patents (PCT), it is possible that the patents found at the INPI are the same as those are in WIPO, as they have the same scope due to the agreement.

Neto et al (2021) using technological prospecting as an innovative perspective described that the number of patents deposited in Brazil is considered low, corroborating the results obtained in the present work.

In according to Kandil (2004), this fact can be explained due to the high cost for the drug development, these costs serve international interests both to justify the high princes of their drugs and to discourage pharmaceutical companies from developing countries, such as Brazil, to invest in discovery of new drugs due to the high cost.

The Derwent Innovations Index database covers over 30.5 million detailed in over 65 million patent documents worldwide, therefore, one can explain the fact of obtaining the greatest number of results (1303) on this platform.
Also according to Table 1, the keyword “Statins”, in a general, is the one that stands out the most, obtaining the greatest amount on the Derwent platform with 1265 patents, 1020 on WIPO and 226 on Espacenet. However, in Brazil, the production of patents on this subject is not expressive when compared to other bases, obtaining only 02 patents found.

Two new analyzes were carried out: In the first one, 546 patents, corresponding to 21.31%, followed by the second screening with the objective of carry out a technological prospection of the HMG-CoA reductase inhibitors produced by different genera of fungi. After reading and checking the detailed descriptions of inventions, another 541 patents were excluded for not meeting the needs of the authors, corresponding to 93.08% of the patents analyzes with duplicity or not related to the production of HMG-CoA reductase inhibitors, inability to extract data or not contain full text available. Thus, 10 patents (1.85%) were selected for analysis according to the objective of the study as shown in Table 2.

**Table 2 - Patents for the production of HMG-CoA reductase inhibitors by microorganisms from 2015 to 2022.**

<table>
<thead>
<tr>
<th>Patent Nº</th>
<th>Publication date</th>
<th>Title</th>
<th>Inventor</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN113881572(A)</td>
<td>04-01-2022</td>
<td>High-yield lovastatin red yeast rice as well as cultivation method and application thereof</td>
<td>Feng; Zhang; Liu; Chen; Li; Zhu (2022)</td>
</tr>
<tr>
<td>CN112779301(A)</td>
<td>02-07-2021</td>
<td>Fermentation of lovastatin from red fermented rice by obtaining a fermentation product such as lovastatin from red fermented rice by inoculating fungal liquido Monascus purpureus into a culture medium containing mainly rice for fermentation</td>
<td>Gao; Jixzhong; Myao (2021)</td>
</tr>
<tr>
<td>WO2020038197(A1)</td>
<td>16-03-2020</td>
<td>The Aspergillus constructo for the production of monacolin J by direct fermentation comprises the complete blockade of polyketide synthase Lovf expression in Aspergillus</td>
<td>Xhuang; Xyang; Lteng (2020)</td>
</tr>
<tr>
<td>CN111718970-A</td>
<td>17-11-2020</td>
<td>High yield lovastatin fungal fermentation method by preparing seed bottle culture medium, inoculating colony suspension, shake culture, preparing fermentation bottle culture medium, colony transplantation and shake culture</td>
<td>Wu; Hzhang; Wzheng (2020)</td>
</tr>
<tr>
<td>CN108977469-A</td>
<td>26-02-2019</td>
<td>Use of rice bran juice for the production of pravastatin by microbial fermentation, where the pravastatin production method involves inoculating activated Actinomadura madurae into the culture medium, adding mevastatin to the medium to ferment the pravastatin</td>
<td>Chen (2019)</td>
</tr>
<tr>
<td>CN109182142 (A)</td>
<td>10/09/2018</td>
<td>New Penicillium crustosum Pc-46 used for lovastatin fermentation production</td>
<td>Xu; Dzheng; Mwang; (2018)</td>
</tr>
<tr>
<td>CN108315265-A</td>
<td>10/09/2018</td>
<td>New strain of Aspergillus versicolor Av-2 useful for the fermentative production of lovastatin</td>
<td>Jiang; Cshou; Zzhang; (2018)</td>
</tr>
<tr>
<td>CN106479900-A</td>
<td>06/01/2017</td>
<td>New strain of Penicillium oxalicum is preserved at Canadian Clinical Trials Coordinating Centre, used to produce lovastatin</td>
<td>Jiang; jqian; Yhan; (2017)</td>
</tr>
<tr>
<td>CN105219653(A)</td>
<td>08-01-2016</td>
<td>New strain Ac-32 of Aspergillus clavatus for high-yield production of lovastatin</td>
<td>Jiang; Hzhang; Mzhang; (2016)</td>
</tr>
<tr>
<td>CN105602856-A</td>
<td>08-01-2016</td>
<td>New strain of Aspergillus niger An-19 used to make lovastatin is preserved at the China Center for Type Culture Collection</td>
<td>Jiang; Hzhang; Xzhang; (2016)</td>
</tr>
</tbody>
</table>

Source: Authors.
Also according to Table 2, it is observed that the patents deposited and selected came from China (09), followed by the World Property Organization Intellectual (WIPO) (01). As a country, China is the main patent holder, signaling its potential for HMG-CoA inhibitor production technologies reductase corresponding to 90% of the patented products. Simão, Wanderley, Nunes and Fritzen-Freire (2022) described the largest deposit of patents by private sector companies in China.

3.1.1 Classification of patent records related to the biotechnological production of statins

On the Derwent platform, 11 patents using the keyword “Production and statins and fungi” were classified in 08 areas of knowledge according to picture in Figure 1. It is observed that 11 documents, 100%, are in the area of “Chemistry”, “Pharmacology Pharmacy” (10 records) with 90, 91%, and the “Biotechnology Applied Microbiology” presented 09 record generating a percentage of 81.82%.

Figure 1 - Patent registration on the DERWENT platform with the keywords “Production and statins and fungi” for the period 2015 to 2022 evaluated by areas of knowledge.

Patents filed are classified according to Category International Patent Office (CIP) which is composed of letters and numbers, divided into sections, classes, subclasses and groups; It is a system recognized worldwide, which has with the objective to standardize the varied themes in the technological scope for an accessible language. Specifically, the classification in which most of the analyzes patents is the C12N area (18) (microorganisms or enzymes; their compositions; propagations, preservation, or maintenance of microorganisms or tissue; genetic or mutation engineering. Culture media), followed by the A61K patents (16) (preparations for medicinal, dental or hygienic purposes) and the third most cited class C12P (12) (fermentation process or processes using enzymes to synthesize a desired chemical composition or compound or to separate optical isomers of a racemic mixture) (Figure 2).
Figure 2 - Number of patents filed classification (CIP) related to biotechnological production of statins.

Source: Derwent Innovations Index (2022).

3.2 Scientific mapping to identify the number of published articles with the biotechnological production of statins

The results obtained in research carried out in scientific databases are described in Table 3, where the total number of articles found in the two databases used in the search with all keywords was 2820, higher than number of patents which was 2561 in the same period, representing 91% of the number of published articles.

Table 3 - Number of articles by keywords in title and abstract retrieved in the Scielo and Pubmed databases from 2015 to 2022.

<table>
<thead>
<tr>
<th>Descritors</th>
<th>Scielo</th>
<th>Pubmed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Portuguese</td>
<td>English</td>
</tr>
<tr>
<td>Statins</td>
<td>112</td>
<td>134</td>
</tr>
<tr>
<td>Production and statins and fungi</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Statins and fungi</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total:</td>
<td>112</td>
<td>134</td>
</tr>
</tbody>
</table>

Source: Authors.

The keyword “statins”, as in the Search for patentes, obtained the highest number of documents in the Scielo and Pubmed databases, obtaining 358 and 2286 articles, respectively.

According to Table 3, as with patentes, the search for articles with the descriptor “Production and statins and fungi” obtained the least publications. However, on the Scielo platform, there was no publication using the descriptors “Production and statins and fungi” and “Statins and fungi” and 130 results for and “Statins and fungi”, which portrays studies scientific studies by other countries on the subject.

The analysis of scientific articles revealed that the main synthesized statin is lovastatin, obtained mainly by Aspergillus terreus (82%) and by diferente species of Monascus sp. (10%) but also by Other genera of fungi filamentous, such as Penicillium sp. (8%), as shown in Figure 3A. At the however, through Figure 3B it can be seen that the main fungal genera
pravastatin producers are *Penicillium* sp. (75%) and *Monascus* sp. (25%) respectively. Namestova et al. (2015), reports the production of the HMG-CoA inhibitor reductase (simvastatin) by *Aspergillus terreus* (Figure 3C).

**Figure 3** - Potential of fungi in the production of statins: (A) Lovastatin; (B) Pravastatin and (C) Simvastatin.

Source: Authors.

### 3.2.1 Use of renewable sources as a strategy for the production of Inhibitors of HMG-CoA reductase

Sinha & Häder (2021), Neto et al., (2019) e Subhan; Farval; Macreadie (2016), we affirm that carbon and nitrogen sources are essential components of the synthesis of metabolites in microorganisms and that the definition which source to use in the process production is critical to define which HMG-CoA reductase inhibitor will be produced, in addition to being related to yield. In this context, the substrates agro-industrial products can be reused as alternative and low-cost sources, in replacement of synthetic sources because they present nutrients such as sugars, fibers, minerals and proteins.

Table 4 depicts the ability of microorganisms to use substrates agroindustries as an alternative source for the production of HMG-CoA inhibitors reductase, converting them into products of high commercial value and contributing to reduction of these materials in the environment. Furthermore, it can be observed that the substrates most used in the production of HMG-CoA reductase inhibitors are: bran wheat (60%), rice husk (25%), corn husk (15%).
Table 4 - Substrates of agro-industrial origin as an alternative source for the production of HMG-CoA reductase inhibitors by filamentous fungi.

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Microorganisms</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wasterwater from sago processing</td>
<td>Aspergillus terreus KPR12</td>
<td>Srinivasan, Thangavelu, Uthandi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2022)</td>
</tr>
<tr>
<td>Wheat bran</td>
<td>Aspergillus flavipes BICC 5174</td>
<td>Seenivasan et al., (2018)</td>
</tr>
<tr>
<td>Palm Seed Cake</td>
<td>Aspergillus wentii NCIM 661</td>
<td>Pallem; Parasa; Manipati, (2018)</td>
</tr>
<tr>
<td>Wheat bran</td>
<td>Aspergillus niger GCBL-45</td>
<td>Javed et al.</td>
</tr>
<tr>
<td></td>
<td>Aspergillus flavipes GCBL-72</td>
<td>(2017)</td>
</tr>
<tr>
<td></td>
<td>Aspergillus flavus GCBL-60</td>
<td></td>
</tr>
<tr>
<td>Olive Pie (Olive Cake); pea pod; potato peel; sugarcane bagasse; wheat bran; rice husks; beet husk; peanut shell</td>
<td>Aspergillus fumigatus</td>
<td>Mouafi; Ibrahim; Elsoud, (2016)</td>
</tr>
<tr>
<td></td>
<td>Aspergillus niger NRRL595</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rhizopus oligosporus NRRL2710</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Penicillium citrinum</td>
<td></td>
</tr>
<tr>
<td>Wheat bran</td>
<td>Monascus Sanguineos</td>
<td>Dikshit; Tallapragada, (2016)</td>
</tr>
</tbody>
</table>

Source: Authors.

4. Final Considerations

From the data found in the specialized literature, it can be observed that biotechnological methods are preferred for the production of HMG-CoA reductase inhibitors that can be biosynthetically obtained as secondary metabolites by several microorganisms, mainly Aspergillus terreus (75%), Penicillium sp. (20%) and Monascus sp. (5%).

The innovations analyzed show the use of secondary metabolites of microorganisms of the same genus, but they differ through their characteristics by to be local strains, in addition to the use of different methods to obtain of HMG-CoA reductase inhibitors.

It is possible to say that innovation in medicines based on biodiversity through the biotechnological production of HMG-CoA reductase inhibitors is a effective alternative for the production of biopharmaceuticals, as it is sustainable process of production of clean technology, a fact that enables competition at a commercial level.

The use of sustainable technology in the pharmaceutical area meets the demands socioeconomic conditions, through the reduction of production costs of the biomolecule and environment, generating an advantageous bioprocess from renewable sources and the minimization of the environmental impact caused by the accumulation of these residues agro-industrial activities in the environment, thus broadening the horizons for innovation in the pharmaceutical sector.

Therefore, the study highlights strategies such as the use of renewable and low-cost sources for the production of HMG-CoA reductase inhibitors, highlighting the substrates wheat bran (60%), rice husk (25%), husk of corn (15%).

Finally, it is worth noting that a perspective to expand the biotechnological production of HMG-CoA reductase inhibitors is related to the challenge of finding new fungi with high enzymatic potential that are able to convert renewable sources of agro-industrial origin into secondary metabolites useful for the production of HMG-CoA reductase inhibitors.
substrates as alternative sources of carbon and nitrogen, and that allow the generation of a sustainable process in the production of these biomolecules. In addition, it is necessary to encourage the protection of technology by individual inventors.

Acknowledgments

The authors are grateful to NPCIAM (Nucleus of Research in Environmental Sciences and Biotechnology), Catholic University of Pernambuco (Recife-PE, Brazil) and Rural Federal University of Pernambuco for the use of the laboratories and materials, CAPES and CNPq for the financial support (Process Nº 88887.703430/2022-00).

References


Chen L. (2019). Use of rice bran juice for the production of pravastatin by microbial fermentation, where the pravastatin production method involves inoculating activated *Actinomadura muretii* into the culture medium, adding mevastatin to the medium to ferment the pravastatin. Patent CN108977469-A.


Gao L.; Jixzhong X.; & Myao Z. (2021). Fermentation ofLovastatin from red fermented rice by obtaining a fermentation product such as Lovastatin from red fermented rice by inoculating fungal liquid of *Monascus parasporus* into a culture medium containing mainly rice for fermentation. Patent CN112779301(A).


Jiang L.; Jqian X.; & Yyhan Z. (2017). New strain of *Penicillium oxalicum* is preserved at Canadian Clinical Trials Coordinating Centre, used to produce lovastatin. Patent CN106479900-A.


